Abstract
We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
Keywords: P2X4Rs, microglia, neuropathic pain, P2X4Rs, microglia, neuropathic pain, Atomic force microscopy, Brain-derived neurotrophic factor, Chemokine (C-C) ligand 2, Central nervous system, Dorsal root ganglion, Anion reversal potential, Eukaryotic translation initiation factor 4E
CNS & Neurological Disorders - Drug Targets
Title:P2X4 Receptors of Microglia in Neuropathic Pain
Volume: 11 Issue: 6
Author(s): Kazuhide Inoue and Makoto Tsuda
Affiliation:
Keywords: P2X4Rs, microglia, neuropathic pain, P2X4Rs, microglia, neuropathic pain, Atomic force microscopy, Brain-derived neurotrophic factor, Chemokine (C-C) ligand 2, Central nervous system, Dorsal root ganglion, Anion reversal potential, Eukaryotic translation initiation factor 4E
Abstract: We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
Export Options
About this article
Cite this article as:
Inoue Kazuhide and Tsuda Makoto, P2X4 Receptors of Microglia in Neuropathic Pain, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581065
DOI https://dx.doi.org/10.2174/187152712803581065 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium
Current Topics in Medicinal Chemistry Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science Nucleic Acid Based Therapeutics for Tumor Therapy
Anti-Cancer Agents in Medicinal Chemistry MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Advanced Membrane Systems for Tissue Engineering
Current Organic Chemistry Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Combined <i>Curcuma longa</i> and <i>Cratoxylum formosum</i> Extracts Possess Anti-liver Cancer and Anti-HBV Activities in HepG2.2.15
Current Traditional Medicine Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry